DepositPhotos/pichetw
BioMarin Pharmaceutical is making a significant move to strengthen its position in the rare disease market with the acquisition of Alesta Therapeutics. The deal will bring clinical-stage asset ALE1 into its pipeline. The transaction is valued at $275 million up front with an additional $215 million tied to development and regulatory milestones. It represents BioMarin’s largest addressable patient population opportunity to date
ALE1 is an orally active small molecule designed to treat hypophosphatasia (HPP), a rare genetic bone disease caused by mutations in the ALPL gene. The drug candidate has the potential to become the first oral therapy for this debilitating condition and is currently being evaluated in an ongoing Phase I/IIa clinical trial (NCT07179640) assessing safety, tolerability, and pharmacokinetics/pharmacodynamics in healthy volunteers and adults with HPP
HPP is a serious condition affecting bone and tooth mineralization that can result in frequent bone fractures, early tooth loss, and in adults, clinically significant muscle weakness, fatigue, and pain. If approved, ALE1 would be the first oral therapy to target inorganic pyrophosphate, the central disease metabolite, with the potential to impact both skeletal and broader manifestations of HPP through systemic correction of disease biology
“ALE1 is a strong strategic fit for BioMarin, bringing a potential oral alternative to the injectable therapies available today for people living with HPP around the world while meaningfully strengthening our early-stage clinical pipeline,” said Alexander Hardy, president and CEO of BioMarin said in a publiclystatementthat was sent toBioXconomywhen contacted for further comment
“This is exactly the kind of opportunity to address a significant unmet need that lets us compete in larger rare disease markets, adding an asset that has the potential to reach our largest addressable patient population.”
The deal has been approved by the boards of directors of both companies. Alesta will spin out all non-ALE1 assets to a new entity prior to closing. Former Alesta employees will transfer to the spinout entity, meaning no Alesta employees will become BioMarin employees as part of the transaction. The deal is expected to close this quarter but is subject to customary closing conditions
Following the close, the ALE1 program will become part of BioMarin’s Skeletal Conditions Business Unit. BioMarin intends to fund the transaction with cash on hand and expects to provide updated full-year 2026 guidance reflecting the acquisition following the closing. Excluding the upfront consideration, the transaction is expected to have a modestly dilutive impact on 2026 financial results
“We chose to partner with BioMarin due to their deep commitment to people living with rare diseases,” said Ilan Ganot, CEO of Alesta. “BioMarin’s global reach, scale, and proven expertise in rare disease drug development make it an ideal partner to advance ALE1 and realize its potential as a promising treatment for patients with HPP worldwide. This acquisition is also a testament to the extraordinary work, scientific expertise, and drug development capabilities of the Alesta team.”
Investival Showcase
|
London
Now firmly established in London’s premier biopharma & medtech partnering week, this is where capital meets innovation, and global leaders come to connect, pitch, and partner
RegisterLearn more
RegisterLearn more
Read more about:
Rare disease
